Year: 1999 Source: British Journal of Psychiatry, v.174, (March 1999), p.275-276 SIEC No: 19990154

The authors draw attention to the high fatality rate associated with the ingestion of orphenadrine, an antipsychotic drug to reduce Parkinsonian symptoms. They found that orphenadrine was the probable cause of death in 57 of 69 patients who were taking anticholinergic anti-Parkinsonian drugs in Norway.